For emerging pharmaceutical companies, one of the most consequential choices is whether and how to outsource essential business processes. The right BPO partner(s) can reduce operational strain, accelerate timelines, and help ensure compliance in a demanding regulatory landscape. Read on to learn about key questions that should guide your thinking.

For emerging pharma, launching a first product is a milestone that triggers a cascade of operational decisions. How your product reaches the patient doesn’t just shape commercial success; it dictates the organizational infrastructure and operations you must establish.

Business assumptions and data inputs are necessary assets for Gross-to-Net forecasting. For pre-launch products, obtaining these data sets and assumptions is often challenging. Here are some best practices to consider.

In collaboration with Twelve Consulting Group, An Argano Company, we recently hosted a webinar titled “Pharma Forecasting Reimagined: Demand & GTN on a Common Platform.” Industry experts Mike McCarthy, Tara Rockers, and Alex Sanchez explored how leading pharma manufacturing teams are modernizing their forecasting approach using Enterprise Performance Management (EPM) platforms.

In the world of pharmaceutical forecasting, especially when it comes to Gross-to-Net (GTN) channel forecasting, staying ahead of market dynamics is both an art and a science. As commercial teams aim to predict customer- and channel-level revenue performance, one of the most effective tools in the toolkit is the Market Events Library.

For many of the manufacturers we work with on Excel-based planning use cases, obtaining data and setting themselves up for success is a struggle. Read on for a good place to start when considering data management steps to support solutions for areas like Pre-Deal Assessment, GTN Channel Forecasting and Analytics in general.

An analysis of the 2028 Medicare Drug Price Negotiations draft guidance and the implications for manufacturers.

Asembia once again delivered on its reputation as the premier event for specialty pharmacy and pharmaceutical distribution, with expanded themes around operational readiness, Gross to Net forecasting, and the need for integrated analytics and scenario planning across the commercialization lifecycle.

New Drug Reporting related to State Price Transparency laws can be a heavy lift. With our guidance and the STARS system, it doesn't have to be.

Optimizing GTN forecasting is a necessity. Get a recap of our webinar with Twelve Consulting covering this and contact us for more info.

New Jersey has released their Drug Affordability Unit website. Manufacturers must submit required information retroactively from 8/1/2024.

State price transparency regulations are ever changing. Read on to learn about the capabilities necessary to manage them.

Emerging pharmaceutical companies often underestimate the extensive preparation required before a drug launch. Effective pre-launch...

Learn how connecting Demand Forecasting and Supply Planning improves both functions leading to optimized GTN forecasts.

Pharmaceutical manufacturers across the board grapple with the complexities of Gross to Net (GTN) forecasting. While the allure of a...

New York's new law requires 60 days advance notice, while parts of Oregon's law are declared unconstitutional.

Pharosity will be attending Asembia Specialty Summit in Las Vegas this year.

Pharosity will be attending the MDRP Conference in New Brunswick, NJ

We are excited to be hosting a webinar with our friends from Twelve Consulting Group titled Connected Planning Across the Pharma Gross to...

A sneak peak at some of the recent efforts we have made to stay current with the ever-changing (and often confusing) regulations.